| Literature DB >> 30713850 |
Mohamed Mansour1,2, Magda F Mohamed3, Abeer Elhalwagi2, Hanaiya A El-Itriby2, Hossam H Shawki2,4, Ismail A Abdelhamid1.
Abstract
Moringa grows in the tropical and subtropical regions of the world. The genus Moringa belongs to family Moringaceae. It is found to possess various medicinal uses including hypoglycemic, analgesic, anti-inflammatory, hypolipidemic, and antioxidant activities. In this study, we investigated the antimicrobial and the anticancer activity of the Moringa peregrina as well as Moringa oleifera leaves extracts grown locally in Egypt. Results indicated that most of the extracts were found to possess high antimicrobial activity against gram-positive bacteria, gram-negative bacteria, and fungus. The survival rate of cancer cells was decreased in both hepatocellular carcinoma (HepG2) and breast carcinoma (MCF-7) cell lines when treated with Moringa leaves extracts. In addition, the cell cycle progression, apoptosis, and cancer-related genes confirmed its anticancer effect. The toxicity of each extract was also tested using the normal melanocytes cell line HFB4. The toxicity was low in both Moringa peregrina and Moringa oleifera leaves extracts. Furthermore, GC/MS analysis fractionized the phytochemicals content for each potential extract. In conclusion, results suggested that the Moringa peregrina and Moringa oleifera leaves extracts possess antimicrobial and anticancer properties which could be attributed to the bioactive phytochemical compounds present inside the extracts from this plant. These findings can be used to develop new drugs, especially for liver cancer chemotherapy.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30713850 PMCID: PMC6332967 DOI: 10.1155/2019/2698570
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1The antimicrobial activity of the. P/H, P/DEE, P/EA, P/MeOH, P/ACN, O/H, O/DEE, O/EA, O/MeOH, and O/ACN extracts were tested for their inhibition effect on (a) Staphylococcus aureus, (b) Streptococcus mutans, (c) Escherichia coli, (d) Pseudomonas aeruginosa, (e) Klebsiella pneumonia, and (f) Candida albicans. Ampicillin antibiotic was used as the positive control for gram-positive bacteria, Gentamicin for gram-negative bacteria, and Nystatin for fungus. Numbers above columns indicate the inhibition zones (mm).
The inhibition percentage of HepG2 and MCF-7 cell lines by each extract used.
|
| % inhibition |
| % inhibition | ||
|---|---|---|---|---|---|
| HepG2 | MCF7 | HepG2 | MCF7 | ||
| P/H | 62.8 | 73.6 | O/H | 73.5 | 61.3 |
| P/DEE | 77.3 | 79.4 | O/DEE | 72.2 | 80.3 |
| P/EA | 78 | 65.7 | O/EA | 80.7 | 63.5 |
| P/MeOH | 69 | 61.3 | O/MeOH | 76.7 | 61.3 |
| P/ACN | 76.7 | 59.7 | O/ACN | 79.7 | 52.8 |
The survival percentage of HFB4 cell line incubated with each extract for 48 h.
| Treatment | % survival | Treatment | % survival | Treatment | % survival |
|---|---|---|---|---|---|
|
|
|
| |||
| P/H | 80 | O/H | 83 | Doxorubicin | 21 |
| P/DEE | 87 | O/DEE | 87 | ||
| P/EA | 75 | O/EA | 80 | ||
| P/MeOH | 77 | O/MeOH | 80 | ||
| P/ACN | 81 | O/ACN | 82 |
Figure 2Cytotoxicity evaluations of the 4 most active. (a) P/DEE extract. (b) P/EA extract. (c) O/DEE extract. (d) O/EA extract. The IC50 values were calculated using Prism software program (GraphPad software incorporated, version 3). The blue curve indicates the nonlinear regression.
Figure 3The effect of. The relative transcription level of 5 cancer-related genes: (a) P53, (b) BAX, (c) CASP3, (d) BCL2, and (e) MMP1 were determined by qRT-PCR from HepG2 cells treated for 48 h. Values above columns indicate the fold change compared to control. Gene expression levels were normalized to GAPDH.
Cell cycle phases and apoptosis of each extract compared to its control.
|
| % | % | % | % |
|---|---|---|---|---|
|
| 55.37 | 38.22 | 0.73 | 5.68 |
|
| 61.8 | 20.28 | 9.58 | 8.34 |
|
| 57.44 | 16.17 | 14.82 | 11.57 |
|
| 14.34 | 16.23 | 52.86 | 16.57 |
|
| 73.11 | 21.69 | 4.36 | 0.84 |
Figure 4. Cells treated for 48 hours with 4 Moringa leaves extracts including (a) P/DEE, (b) P/EA, (c) O/DEE, (d) O/EA, and (e) untreated cells as controls. The cell cycle distribution was determined by propidium iodide staining (PI) and flow cytometry. Left panels show the distribution and the percentage of cells in phases of the cell cycle. Right panels show the distribution and the percentage of cells of apoptotic cells (Annexin+). The cell cycle phases G1, S, and G2/M are indicated over the peaks. PI: cell survival marker; Annexin V: apoptotic marker.
Figure 5GC/MS chromatograms of the active. The chromatograms of (a) P/DEE, (b) P/EA, (c) O/DEE, and (d) O/EA extracts were analyzed using a GC (Agilent Technologies 7890A) interfaced with a mass selective detector (MSD, Agilent 7000) equipped with a nonpolar Agilent HP-5ms ((5%-phenyl)-methylpolysiloxane) capillary column. The carrier gas was helium with a linear velocity of 1 ml/min. The injector and detector temperatures were 200 and 250°C, respectively. A volume of 1 µl of each extract was injected. The MS operating parameters were as follows: Ionization potential 70 eV, interface temperature 250°C, and acquisition mass range 50-800 m/z.
Compounds found in each extract using the GC/MS analysis.
| Extract | (RT min) Compounds names |
|---|---|
| P/DEE | (9.065) Sorbitol, (10.809) Hexamethylbenzene, (11.502) Butylated Hydroxytoluene, (11.9) Oleic Acid, (13.374) 6-tert-Butyl-2,4-dimethylphenol, (13.971) Palmitaldehyde, (14.116) Levomenthol, (14.219) Isophytol, (14.83) Isopropyl palmitate, (16.084) Isopropyl linoleate, (16.225) Tetracosanoic acid, (17.668) Methyl tridecanoate, (18.245) Arachic acid, (20.25) Hexacosane, (20.865) L-Ascorbic acid, 6-octadecanoate, (21.41) Octacosane, (21.524) Erucic acid and (22.71) Triacontane |
|
| |
| P/EA | (10.816) Hexamethylbenzene, (11.512) Butylated Hydroxytoluene, (11.902) Oleic Acid, (12.786) Phytol, (13.164) Methyl tetradecanoate, (13.377) 6-tert-Butyl-2,4-dimethylphenol, (13.974) Palmitaldehyde, (14.109) Levomenthol, (14.24) Isophytol, (14.36) Hexadecanoic acid & methyl ester, (14.884) Isopropyl palmitate, (15.407) Linolenic acid & methyl ester, (15.772) Methyl stearate, (16.085) Isopropyl linoleate, (16.277) Tetracosanoic acid, (17.569) 2-Hexadecoxyethanol, (17.668) Methyl tridecanoate, (18.23) Arachic acid, (18.779) Salsoline, (20.25) Hexacosane, (20.898) L-Ascorbic acid & 6-octadecanoate, (21.411) Octacosane and (22.715) Triacontane |
|
| |
| O/DEE | (6.567) |
|
| |
| O/EA | (10.38) Retinol, (11.502) Butylated Hydroxytoluene, (12.167) 1-Hexadecanol, (13.164) Methyl tetradecanoate, (13.943) Palmitaldehyde, (14.109) Levomenthol, (14.215) Isophytol, (14.399) Hexadecanoic acid & methyl ester, (14.832) Isopropyl palmitate, (15.407) Linolenic acid & methyl ester, (15.771) Methyl stearate, (16.083) Isopropyl linoleate, (20.25) Hexacosane and (22.718) Triacontane. |
Figure 6Chemical structure of the bioactive compounds from. The major bioactive compounds were separated and identified from the 4 Moringa leaves extracts using the GC/MS. The name of each compound is indicated.